Targeted Oncology presents Precision Medicine, a video series featuring oncology experts discussing how to use a more customized approach when treating patients with cancer.
April 6th 2022
Shaji Kumar, MD, and Jonathan Kaufman, MD, discuss the role of BCL-2 proteins in multiple myeloma treatment and recent safety and efficacy data on BCL-2 inhibitors.
November 23rd 2021
Two leading experts in lung cancer provide insights on therapies targeting ALK mutations patients with non-small-cell lung cancer.
October 29th 2021
Reactions to recent data on the integration of CD19-targeted therapies into the treatment of patients with diffuse large B-cell lymphoma.
October 8th 2021
John DiPersio, MD, PhD, and Michael Bishop, MD, review the use of JAK inhibitors in chronic GvHD and practical considerations for disease management.
September 30th 2021
Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss and compare BTK inhibitors used as targeted therapy for B-cell malignancies, taking into account data from clinical trials and their personal experiences.
September 15th 2021
Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, discuss the importance of CD19-targeted therapy as a promising option in the relapsed/refractory DLBCL setting.
September 2nd 2021
Future implications for palliative therapy with selective immunomodulating microtubule binding agents as prevention against chemotherapy-induced neutropenia in high-risk patients with solid tumors.
August 12th 2021
Joel Neal, MD, PhD, and Alexander I. Spira, MD, PhD, FACP, talk about the role of EGFR, particularly exon 20 insertion, in NSCLC growth and progression, and review the mechanism of action and current safety and efficacy data from the mobocertinib trial.
July 30th 2021
Experts discuss the role of CD19 in the therapeutic landscape for patients with transplant-ineligible relapsed/refractory DLBCL.